Building Resilience and Agility in the Pharma Supply Chain
On demand webinar recording - now available
Fill the details to view the Webinar
Supply disruptions due to Covid-19 and raw material shortages have significantly impacted pharmaceutical organizations. Increasing demands and limitations in logistics and courier services further tested the supply chains. With new challenges and various environmental factors coming into place, pharmaceutical organizations have embarked on adopting digital analytics , new collaborations with government agencies , focus on sustainable supply chain, and changing the organization's internal structure for focused decision making.
In this webinar, we will take a closer look on the API supply chain and real live case studies on how to predict the impact of disruptions and achieve sustainability targets.
What you will learn:
#1 Global supply chain intelligence and how to - predict the impact of disruptions
#2 Integrated business planning
#3 Sustainable supply chains: Reducing the carbon footprint in - the supply chains
#4 Managing Covid-19 induced disruptions and robust business continuity plans
Speakers
Dr. Ravi Prakash Mathur
Vice President and Global Head of Logistics and Supply Chain Excellence Dr. Reddy’s Laboratories Ltd.
Summary of the Webinar
In this webinar, Dr. Ravi Prakash Mathur, Vice President and Global Head of Logistics and Supply Chain Excellence, Dr. Reddy's Laboratories Ltd, addresses - the API supply chain challenges and supply chain management in the pharmaceutical industry complemented with live case studies on how to predict the impact of supply disruptions and achieve sustainability targets.
The first section of the webinar provides insights on sustainability pharmaceutical supply chain focusing on reducing the carbon footprint in the supply chains and logistics and Dr. Reddy's journey in sustainability so far, covering aspects of product responsibility, transparency, operational excellence, and human dignity, equal opportunity, and community development.
The following section covers - managing COVID-19 induced disruptions and business continuity planning and interventions in response to the pandemic and supply chain management in pharmaceutical industry. The role of collaboration in managing disruptions – Strong partner network, cross-industry collaboration groups and opening to new possibilities, leveraging data for LDM & reviewing operations, slicing, and dicing of data for identifying levers for LDM and third-party risk management for sourcing.
The next section of the webinar gives information on digital transformation, integrated business planning (IBP) - project O2: one team, one plan vision, and key objectives, IBP platform features, framework, cross-functional processes, and change management steps. The final session covers – global supply chain intelligence, predicting the impact of disruptions, market intelligence, and critical benefits of procurement dashboards.
Pharmaceutical supply chain management have become complex and become prone to disruptions. As a result, there is a need to keep an eye on and be aware of emerging external scenarios and assess their impact on customer product availability. Supply uncertainty also impacts organizational performance and must synchronize the business processes to create visibility of various performance indicators in advance.
Are you interested in learning more about our global supply chain intelligence, pharmaceutical supply chain, integrated business plan, carbon footprint, managing COVID-19 induced disruptions, and robust business continuity plans? Then contact us at [email protected]
Estamos aqui para ajudar, se tiver algum requisito específico do seu país.
Aviso legal
Nenhuma informação neste site, incluindo qualquer referência a qualquer produto ou serviço, constitui uma oferta de venda ou pode ser interpretada como representando uma oferta de venda. Produtos protegidos por patentes válidas não são oferecidos ou fornecidos para uso comercial. No entanto, em certos casos, a critério exclusivo do Dr. Reddy e sujeito a requisitos legais locais, as quantidades de pesquisa de tais produtos podem ser oferecidas para fins de submissões regulatórias sob a Seção 107A da Lei de Patentes da Índia (isenção Bolar), onde quer que tais isenções regulatórias existam. Os compradores devem fazer sua avaliação independente do produto ou serviço, incluindo o cenário de patentes em seus respectivos mercados e serão responsáveis por todas as responsabilidades relacionadas a patentes. O Dr. Reddy se isenta de todas as garantias, expressas ou implícitas, incluindo, entre outras, garantias de comercialização, adequação a uma finalidade específica e não violação.